Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results - Esperion Therapeutics (NASDAQ:ESPR)

CN to Report Fourth-Quarter and Full-Year 2022 Financial and Operating Results on January 24, 2023

MONTREAL, Jan. 09, 2023 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) will issue its fourth-quarter and full-year 2022 financial and operating results after…

Nova to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

/PRNewswire/ -- Nova (NASDAQ: NVMI), a leading innovator and key provider of metrology solutions for advanced process control used in semiconductor...

Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results

– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023...

Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results - Esperion Therapeutics (NASDAQ:ESPR)

– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive milestone payments from partners upon regulatory approvals – – Fourth quarter 2022 U.S. net product revenue estimated between $14.4 to $15.1 million, FY growth between 38% and 40% year over year – – New partnership with RFK Racing to increase brand awarene…

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update

Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and provided product revenue gu

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

Real-Time News, Market Data, and Stock Quotes for Healthcare Stocks @ healthstockshub.com